Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Yungen Xu"'
Autor:
Jingjing Li, Kai Zhang, Di Wu, Lianjie Ren, Xinyu Chu, Chao Qin, Xiaopeng Han, Taijun Hang, Yungen Xu, Lei Yang, Lifang Yin
Publikováno v:
Asian Journal of Pharmaceutical Sciences, Vol 16, Iss 6, Pp 772-783 (2021)
Strong infectivity enables coronavirus disease 2019 (COVID-19) to rage throughout the world. Moreover, the lack of drugs with definite therapeutic effects further aggravates the spread of the pandemic. Remdesivir is one of the most promising anti-sev
Externí odkaz:
https://doaj.org/article/da579591924e4d26a3f0507c270dcacd
Autor:
Yixuan Tang, Shihui Huang, Xingxing Chen, Junzhang Huang, Qianwen Lin, Lei Huang, Shuping Wang, Qihua Zhu, Yungen Xu, Yi Zou
Publikováno v:
Molecules, Vol 27, Iss 19, p 6637 (2022)
Protein arginine methyltransferases 5 (PRMT5) is a clinically promising epigenetic target that is upregulated in a variety of tumors. Currently, there are several PRMT5 inhibitors under preclinical or clinical development, however the established cli
Externí odkaz:
https://doaj.org/article/83ebffede0804a04a73ec63580c1e62c
Publikováno v:
Pharmaceuticals, Vol 15, Iss 7, p 801 (2022)
Limonin is one of the research hotspots in natural drug development. However, its low solubility in water leads to poor oral bioavailability, discouraging the further study of its potential as a candidate compound. In order to overcome this limitatio
Externí odkaz:
https://doaj.org/article/ab21410390cd4d388ad974977d1fb592
Autor:
Hongbo Zhang, Yu Xia, Chunqiu Yu, Huijie Du, Jinchang Liu, Hui Li, Shihui Huang, Qihua Zhu, Yungen Xu, Yi Zou
Publikováno v:
Molecules, Vol 26, Iss 11, p 3347 (2021)
Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in canc
Externí odkaz:
https://doaj.org/article/161639fb628244d886a74cd15e6fd6b3
Autor:
Lingzhi Zhang, Qiurong Ju, Jinjin Sun, Lei Huang, Shiqi Wu, Shuping Wang, Yin Li, Zhe Guan, Qihua Zhu, Yungen Xu
Publikováno v:
Molecules, Vol 25, Iss 23, p 5693 (2020)
Concomitant inhibition of MAPK and PI3K signaling pathways has been recognized as a promising strategy for cancer therapy, which effectively overcomes the drug resistance of MAPK signaling pathway-related inhibitors. Herein, we report the scaffold-ho
Externí odkaz:
https://doaj.org/article/a0cb71a2e42343b7bb95b5ffeb1612b0
Autor:
Lingyan Xu, Zhiyun Ren, Frances E. Chow, Richard Tsai, Tongzheng Liu, Flavio Rizzolio, Silvia Boffo, Yungen Xu, Shaohui Huang, Carol F. Lippa, Yuesong Gong
Publikováno v:
Neural Plasticity, Vol 2017 (2017)
Synaptic loss is the structural basis for memory impairment in Alzheimer’s disease (AD). While the underlying pathological mechanism remains elusive, it is known that misfolded proteins accumulate as β-amyloid (Aβ) plaques and hyperphosphorylated
Externí odkaz:
https://doaj.org/article/85cfa96468324a849d4d5daf78bdd1ae
Autor:
Guangchao He, Sheng Wan, Yunze Wu, Zhaoxing Chu, Hui Shen, Shan Zhang, Linya Chen, Zijing Bao, Shuhui Gu, Junzhang Huang, Lei Huang, Guoqing Gong, Yi Zou, Qihua Zhu, Yungen Xu
Publikováno v:
Journal of Medicinal Chemistry. 65:14348-14365
Indoleamine 2,3-dioxygenase 2 (IDO2), a closely related homologue of well-studied immunomodulatory enzyme IDO1, has been identified as a pathogenic mediator of inflammatory autoimmunity in preclinical models. Therapeutic targeting IDO2 in autoimmune
Autor:
Fuqiang Zheng, Jianhui Zhou, Feifei Fang, Jiyuan Li, Jing Wang, Miao Zheng, Hong Liu, Yungen Xu, Yu Zhou
Publikováno v:
Organic Letters. 24:5688-5692
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 49:567-576
Thrombin has long been considered a desirable antithrombotic target, but anti-thrombin therapy without anti-platelet therapy has never achieved the ideal effect. HY023016, derived from dabigatran etexilate, exhibited a potent antithrombotic efficacy.
Autor:
Zhifeng Wei, Jinxi Shan, Kewen Peng, Hui Shen, Zhang Shan, Xin He, Yiran Ge, He Guangchao, Qihua Zhu, Chu Zhaoxing, Huanhuan Wu, Yungen Xu, Wang Junjie, Yi Zou
Publikováno v:
Journal of Medicinal Chemistry. 64:17950-17968
Indoleamine 2,3-dioxygenase-1 (IDO1) plays an important role in tumor immune escape. However, unsatisfactory clinical efficacies of selective IDO1 inhibitors have impeded their further development, suggesting that they do not exert sufficient antitum